{"schema_version":"secwatch.filing_event.v1","accession":"0001199835-24-000220","form_type":"8-K","ticker":null,"cik":"0001504239","company_name":"Point of Care Nano-Technology, Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.714295+00:00","generated_at":"2026-06-01T05:16:52.710078+00:00","sec_items":["1.01","2.01","5.01","1.1","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PCNT acquires EZ Saliva diagnostic assets, issues 66M shares; control shifts to Dr. Guirguis","bullets":["Acquired substantially all assets of Point of Care Nano-Technology, LLC, including EZ Saliva test kit IP and $101,400 cash, for 66M restricted shares.","Dr. Raouf Guirguis became director and Chief Scientific Officer; his group obtained ~48.4% of outstanding common stock.","Nathan Keele joined board with ~26.5% stake; previous controller Nicholas DeVito surrendered super-majority preferred for 5M common shares, remains CEO.","Entered exclusive perpetual license with Zeus Diagnostics for oral-fluid patents in N.America; $35K upfront plus 7.5% royalty.","Company to focus on commercializing EZ Saliva products; financial statements of acquired business to be filed by amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001199835-24-000220","json":"https://secwatch.observer/filing/0001199835-24-000220.json","markdown":"https://secwatch.observer/filing/0001199835-24-000220.md","text":"https://secwatch.observer/filing/0001199835-24-000220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/0001199835-24-000220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/pcnt-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:16:52.710078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4deaa1740ecbb570dc2ff294f35f8c110bb3dce3","claim":"Point of Care Nano-Technology, Inc. completed an acquisition involving Point of Care Nano-Technology, LLC for 66,000,000 restricted shares of the Company’s common stock (closed 2024-05-20).","evidence_excerpt":"of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company is issuing to Point and/or its designees 66,000,000 restricted shares of the Company’s common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/0001199835-24-000220-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Point of Care Nano-Technology, LLC"},{"label":"Consideration","value":"66,000,000 restricted shares of the Company’s common stock"},{"label":"Closing","value":"2024-05-20"}],"fact_type":"ma_transaction"},{"claim_id":"82a7a07748c394e6e84c076b22a1a29b9872f9db","claim":"Point of Care Nano-Technology, Inc. underwent a change of control involving Point of Care Nano-Technology, LLC for 66,000,000 restricted shares of the Company’s common stock (closed 2024-05-20).","evidence_excerpt":"of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company is issuing to Point and/or its designees 66,000,000 restricted shares of the Company’s common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1504239/000119983524000220/0001199835-24-000220-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Point of Care Nano-Technology, LLC"},{"label":"Consideration","value":"66,000,000 restricted shares of the Company’s common stock"},{"label":"Closing","value":"2024-05-20"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}